Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) will be issuing its quarterly earnings data before the market opens on Tuesday, February 27th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.
Fulcrum Therapeutics Price Performance
NASDAQ:FULC opened at $9.60 on Monday. The business has a 50 day moving average of $7.59 and a 200 day moving average of $5.54. The company has a market capitalization of $593.47 million, a price-to-earnings ratio of -5.71 and a beta of 2.25. Fulcrum Therapeutics has a 1-year low of $2.25 and a 1-year high of $9.90.
Institutional Trading of Fulcrum Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc increased its stake in shares of Fulcrum Therapeutics by 8.3% during the fourth quarter. Legal & General Group Plc now owns 13,925 shares of the company’s stock valued at $101,000 after buying an additional 1,066 shares during the period. Amalgamated Bank increased its stake in shares of Fulcrum Therapeutics by 42.1% during the fourth quarter. Amalgamated Bank now owns 5,724 shares of the company’s stock valued at $42,000 after buying an additional 1,696 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Fulcrum Therapeutics by 2.4% during the first quarter. Charles Schwab Investment Management Inc. now owns 72,209 shares of the company’s stock valued at $1,708,000 after buying an additional 1,724 shares during the period. Northern Trust Corp increased its stake in shares of Fulcrum Therapeutics by 1.4% during the fourth quarter. Northern Trust Corp now owns 144,965 shares of the company’s stock valued at $979,000 after buying an additional 1,984 shares during the period. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Fulcrum Therapeutics by 13.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 17,020 shares of the company’s stock valued at $124,000 after buying an additional 2,009 shares during the period. Institutional investors own 89.83% of the company’s stock.
Wall Street Analysts Forecast Growth
Read Our Latest Research Report on Fulcrum Therapeutics
Fulcrum Therapeutics Company Profile
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia is under phase I clinical trial.
Read More
- Five stocks we like better than Fulcrum Therapeutics
- How to Calculate Return on Investment (ROI)
- MarketBeat Week in Review – 2/19 – 2/23
- How to Capture the Benefits of Dividend Increases
- How to invest in apparel stocks
- Energy and Oil Stocks Explained
- Stock ideas from the 2024 Microcap Conference
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.